The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.

ROCHESTER, Minn. (KTTC) – A Winona industrial supply company provided assistance to a Wisconsin high school student’s science ...

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Now that the data is going to a 23andMe-adjacent nonprofit, which is also making similar promises, I guess nothing much has ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to read an analysis of REGN stock now.

"Find a secure way to download that data first ... users who want to protect their genetic information before the company completes its sale to Regeneron.

Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical ...

CHENNAI: Biocon Biologics, the biosimilars subsidiary of Biocon Ltd, said on Friday that Health Canada has granted a Notice ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

In January of 2024, the class action lawsuit was filed against the company, alleging that 23andMe failed to protect the data ...